March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...

"Thank you to all who have been on this journey with us and thank you to those continuing the Sutro journey as we part company," the outgoing CEO said. Sutro Biopharma CEO Bill Newell left the ...

Oppenheimer downgraded Sutro Biopharma (STRO) to Perform from Outperform. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Sutro Biopharma (STRO), with a market capitalization of $74.7 million, reported its Q4 2024 earnings on March 13, 2025, meeting its earnings per share (EPS) forecast of -0.83. The company exceeded ...

The Company will continue to explore global out-licensing opportunities for luvelta, as Sutro still believes in its potential to provide significant benefit to patients with unmet need. Further, given ...

Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is deprioritizing development of luvelta in order to focus resources ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash ...

Sutro Biopharma will cut its workforce by half after completing a strategic review of the company's portfolio. Its top executive will also step down, as it switches focus to its next-generation ...

SOUTH SAN FRANCISCO - Sutro Biopharma, Inc. (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced a strategic shift in its pipeline focus ...